Humacyte’s mission is to become the leading company in novel, off-the-shelf extracellular matrix tissue products that significantly improve treatment outcomes in patients with a variety of disease conditions. Humacyte is a privately-held company that was founded in 2004 by Laura Niklason, MD. PhD., a world leader in tissue engineering, and currently Professor of Biomedical Engineering and Anesthesia at Yale University. Niklason co- founded Humacyte along with Drs. Shannon Dahl and Juliana Blum. Humacyte’s research platforms and core technologies are based on the research conducted by Drs. Niklason and Dahl at Duke University, and by Dr. Niklason at the Massachusetts Institute of Technology in the laboratory of Dr. Robert Langer.
Humacyte’s other senior management, advisors and board of directors have extensive, proven experience in product development, clinical trials, regulatory affairs, business and commercial development, finance and intellectual property management.
Humacyte’s business model is to develop and commercialize our products in the US, and potentially license commercialization rights to a corporate partner in ex-US markets. Our corresponding development strategy is to aim for the fastest speed to market by pursuing approval for indications with the greatest chance of clinical success and safety, through well-established regulatory pathways for approval.